MAM
VIVO

Martingale Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Martingale Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,387
Closed -$1.37M – 911
2022
Q4 		$1.37M Hold
41,387
– – 0.03% 360
2022
Q3 		$1.31M Sell
41,387
-15,424
-27% -$499K 0.03% 363
2022
Q2 		$1.73M Sell
56,811
-21,181
-27% -$573K 0.03% 312
2022
Q1 		$2.03M Buy
77,992
+7,629
+11% +$181K 0.03% 286
2021
Q4 		$1.44M Buy
70,363
+24,602
+54% +$472K 0.02% 394
2021
Q3 		$881K Buy
45,761
+5,705
+14% +$114K 0.01% 538
2021
Q2 		$889K Sell
40,056
-12,699
-24% -$269K 0.01% 431
2021
Q1 		$1.39M Sell
52,755
-10,715
-17% -$255K 0.02% 343
2020
Q4 		$1.19M Sell
63,470
-12,995
-17% -$243K 0.01% 401
2020
Q3 		$1.3M Buy
76,465
+897
+1% +$17.4K 0.02% 556
2020
Q2 		$1.76M Sell
75,568
-74,056
-49% -$1.07M 0.02% 570
2020
Q1 		$1.26M Sell
149,624
-95,294
-39% -$802K 0.02% 613
2019
Q4 		$2.39M Sell
244,918
-117,818
-32% -$1.11M 0.02% 560
2019
Q3 		$3.44M Buy
362,736
+145,638
+67% +$1.53M 0.04% 464
2019
Q2 		$2.58M Sell
217,098
-114,304
-34% -$1.38M 0.03% 533
2019
Q1 		$5.84M Buy
331,402
+37,900
+13% +$631K 0.06% 320
2018
Q4 		$5.1M Buy
293,502
+20,600
+8% +$351K 0.07% 313
2018
Q3 		$4.07M Buy
272,902
+3,702
+1% +$57.4K 0.05% 374
2018
Q2 		$4.28M Buy
269,200
+1,200
+0.4% +$17.9K 0.05% 353
2018
Q1 		$3.81M Buy
268,000
+87,010
+48% +$1.29M 0.05% 362
2017
Q4 		$2.53M Buy
180,990
+87,815
+94% +$1.29M 0.03% 463
2017
Q3 		$1.33M Buy
93,175
+7,806
+9% +$112K 0.02% 656
2017
Q2 		$1.34M Buy
85,369
+19,815
+30% +$285K 0.02% 651
2017
Q1 		$905K Sell
65,554
-180,217
-73% -$2.52M 0.01% 737
2016
Q4 		$4.35M Buy
245,771
+22,008
+10% +$387K 0.06% 348
2016
Q3 		$4.32M Buy
223,763
+127,801
+133% +$2.5M 0.06% 315
2016
Q2 		$1.87M Sell
95,962
-399
-0.4% -$7.83K 0.03% 339
2016
Q1 		$1.99M Sell
96,361
-440
-0.5% -$8.67K 0.04% 330
2015
Q4 		$1.99M Sell
96,801
-322
-0.3% -$6.17K 0.04% 307
2015
Q3 		$1.66M Buy
97,123
+39,304
+68% +$718K 0.04% 341
2015
Q2 		$1.08M Buy
57,819
+15,860
+38% +$294K 0.03% 499
2015
Q1 		$801K Buy
41,959
+15,305
+57% +$283K 0.02% 596
2014
Q4 		$439K Buy
26,654
+310
+1% +$5.32K 0.01% 722
2014
Q3 		$467K Sell
26,344
-17,502
-40% -$344K 0.01% 684
2014
Q2 		$905K Sell
43,846
-550
-1% -$11.3K 0.03% 554
2014
Q1 		$968K Buy
44,396
+5,055
+13% +$116K 0.03% 504
2013
Q4 		$1.04M Sell
39,341
-1,003
-2% -$24.7K 0.04% 520
2013
Q3 		$954K Buy
40,344
+101
+0.3% +$2.36K 0.03% 534
2013
Q2 		$866K Buy
+40,243
New +$868K 0.03% 556

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Martingale Asset Management's VIVO Position: Q1 2023 in Review

Martingale Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 41,387 shares — an estimated $1.37M sold.

Martingale Asset Management first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $5.84M in Q1 2019. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Martingale Asset Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Martingale Asset Management sold 41,387 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.37M.
  • Martingale Asset Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Martingale Asset Management's Meridian Bioscience Inc position peaked at $5.84M in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Martingale Asset Management's 13F filing for Q1 2023, filed 12 May 2023.